The Blood Industry
- The U.S. blood market was worth $7.8 billion in 2007. It should reach $9.5 million by 2012, a compound annual growth rate (CAGR) of 5.7%.
- Products used for collecting, processing and transfusing blood will grow from a $1.6 billion segment in 2007 to $2.2 billion by the end of the study period.
- Major driving forces in the industry include the cost of collection and processing, and changes in the incidences of catastrophes requiring blood transfusions.
The goal of this study on the blood industry is to describe and analyze the current markets for blood products, blood tests, and blood processing equipment as well as present important new developments affecting every aspect of this industry. In addition, the report provides an analysis of market value forecasted through 2012 in constant dollars and participating company profiles. The study covers the major aspects of blood and plasma collection/transfusion, including autologous donations, apheresis, fractionation, blood salvage, and stem cells. The major plasma products such as coagulation factors, human serum albumin, and immunoglobulins are analyzed as well. The scope and character of the blood testing segment is constantly changing so the impact of new products, technologies, and equipment are analyzed.
The study also covers federal regulation of the blood supply, blood system management, an analysis of the companies serving these markets, the international developments in blood banking, and related areas as well as research and patents that will affect the future of the blood industry.
SCOPE OF STUDY
This report contains:
- Descriptions of various types of blood and plasma collection and transfusion technologies including autologous donations, apheresis, fractionation, blood salvage and stem cells, and major plasma products such as coagulation factors, human serum albumin
- The current U.S. blood industry market status, with trends and forecasts for growth over the next 5 years
- Technological issues including the latest trends and a thorough patent analysis
- Analysis of federal regulations concerning blood supply and management
- Discussion of the international markets for various blood and blood-related products.
METHODOLOGY AND INFORMATION SOURCES
Data for this study were collected using both primary and secondary data research techniques. A literature search of BCC's extensive library as well as scientific, medical, and business libraries was conducted. On-line databases and government sources were consulted as well. Extensive interviews with industry personnel, scientists, professional and trade organizations, government agency personnel, observers, scientists, and industry professionals were conducted.
Data collected were analyzed by BCC personnel to determine specific findings and forecasts. Once these forecasts were obtained, they were validated with industry experts; consequently, all estimates provided in this report represent a consensus of BCC personnel, industry participants, and industry observers. Since some segments of this report are not routinely measured, BCC derived estimates from a variety of analogous sources. Whenever market estimates are derived, they are fully noted. It should be pointed out that while many factors were considered in constructing different models, the projections are ultimately speculative. As a composite of the opinions and assessments of interviewees, the author, other analysts, and secondary sources, these projections represent something of a consensus. However, all recognize that the relative importance of selected factors could change at any time with new technologies and new products and, thus, change the direction of the market projections. All forecasts use constant 2007 dollars.
Mary Anne Crandall has been publishing market research in the life sciences for more than 17 years. She holds a Master of Science Degree in psychology, and is the founder and CEO of Mountaintop Medical, LLC, a consulting firm in Oregon. She has taught at Southern Oregon University for more than 16 years, and before joining BCC's analytical team, she published with Frost & Sullivan, Theta Reports, FIND/SVP, MDI, FeedBack Research Services, Prognosis and Hall Enterprises. Ms. Crandall specializes in prescription pharmaceutical markets.
Sales for the blood and blood components segment and the plasma derived segment of the U.S. blood market will approach $6.6 billion in 2005 and are expected to approach $9.9 billion in 2010, rising at an average annual growth rate (AAGR) of 8.5%.
The collection and processing products segment will grow from over $1.8 billion to nearly $2.5 billion at an AAGR of 7%.
The driving forces of the industry are collection and processing cost, technology, an aging population and the changes in the incidence of diseases, surgical procedures and catastrophes that require transfusions.
Safety of the blood supply is the primary issue and donation testing has been enhanced with the greater use of nuclear amplifications testing methods.
The U.S. market for products used in the blood business are expected to exceed $6.1 billion in 2001.
The market is projected to reach nearly $8.7 billion by 2006, growing at an average annual rate (AAGR) of 7.2%.
The largest segment, blood components and plasma products, makes up over 80% of the market. Growing at an AAGR of 7.8% through 2005, these products will rise to command nearly 84% of the total market.
Equipment, blood tests and additional consumables will grow at an AAGR of 4.3% from $1.2 billion in 2001 to over $1.4 billion in 2006.